Suven Life Sciences Limited, a active public limited company, was established on 09 March 1989 in Hyderabad, Telangana, India. Engaging in pharma contract r&d within the professional, scientific and technical sector, it holds CIN: L24110TG1989PLC009713. Registered under ROC Roc Hyderabad. it is listed on BSE: 530239 and NSE: SUVEN. It has an authorized capital of ₹50.00 Cr and a paid-up capital of ₹22.75 Cr.
Formerly known as Suven Synthesis Ltd, Suven Pharmaceuticals Pvt Ltd. It upholds a compliant status. In 2023, it reported revenue of ₹21.99 Cr and a net worth of ₹853.44 Cr. Employing 137 professional, Its leadership includes Santanu Mukherjee (Director), Sudharani Jasti (Whole-Time Director), Venkateswarlu Jasti (Managing Director). Past directors included Sambasiva Ramachandran, Hanumantha Rao Kokkonda, Santanu Mukherjee. It holds no open charges and ₹239.04 Cr settled loans. Its latest AGM occurred on 22 August 2025, with the balance sheet filed on 31 March 2025. It is based at Door No. 8-2-334, 6Th Floor, Sde Serene Chambers Road No. 5, Avenue 7, Banjara Hills, Hyderabad, Telangana, 500034.
L24110TG1989PLC009713
009713
09 March 1989
₹50.00 Cr
₹22.75 Cr
Roc Hyderabad
Listed (BSE: 530239, NSE: SUVEN)
Active
Explore comprehensive insights into Suven Life Sciences Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Santanu Mukherjee | Director | 15 May 2018 | Current |
| Sudharani Jasti | Whole-Time Director | 04 Jan 2013 | Current |
| Venkateswarlu Jasti | Managing Director | 04 Jan 2010 | Current |
| Vajja Sambasiva Rao | Director | 30 Jan 2024 | Current |
| Seyed Ehtesham Hasnain | Director | 30 Apr 2010 | Current |
| Ananthasai Padmaja Jasthi | Director | 14 Nov 2018 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 27 Jul 2010 | Past |
| Pramod Abcsdd | Company Secretary | 10 Jan 2020 | Past |
| Pramod Abcsdd | Additional Director | 14 Aug 2018 | Past |
| Pramod Abcsdd | Ceo | - | Past |
| Pramod Abcsdd | Additional Director | 04 Mar 2024 | Past |
| Pramod Abcsdd | Additional Director | 27 Jul 2010 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Suven Life Sciences Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 28.13% increase. The company also saw a substantial improvement in profitability, with a 44.47% increase in profit. The company's net worth Soared by an impressive increase of 79.3%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Suven Life Sciences had a promoter holding of 69.56% and a public holding of 30.43%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹2,390,412,500.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Dec 2012 | Bank Of Bahrain And Kuwait Bsc | ₹6.00 Cr | Satisfied |
| 24 Aug 2012 | Bank Of Bahrain And Kuwait Bsc | ₹30.00 Cr | Satisfied |
| 17 Feb 2011 | Bank Of India | ₹22.63 Cr | Satisfied |
| 14 Jul 2010 | State Of Bank Patiala | ₹20.00 Cr | Satisfied |
| 30 Aug 2007 | State Bank Of India | ₹25.35 Cr | Satisfied |
Explore comprehensive loan charge details -
Suven Life Sciences has a workforce of 137 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Suven Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Suven Life Sciences's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Suven Life Sciences Limited last Annual general meeting of members was held on 22 Aug 2025 as per latest MCA records. was completed.
The activity Suven Life Sciences Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad. was completed.
Progress on Vajja Sambasiva Rao was appointed as a Director was appointed as a Director on 30 Jan 2024 & has been associated with this company since 1 year 9 months . was documented.
The activity A charge registered on 06 Dec 2012 via Charge ID 10393384 with Bank Of Bahrain And Kuwait Bsc was fully satisfied on 07 Jan 2021. was completed.
A charge registered on 26 Feb 1990 via Charge ID 90135165 with State Bank Of India was fully satisfied on 03 Dec 2020. was recorded as a recent event.
Progress on Mohan Kumar Mallarapu was appointed as a CFO was appointed as a CFO on 10 Jan 2020 & has been associated with this company since 5 years 10 months . was documented.
When your Alzheimer's drug fails in Phase 2 but you still wanna try Phase 3. 💸💊💭 Not even a ₹400 crore loss can stop Venkat Jasti from pursuing his dream of finding a cure. 💪🏼💰 But let's be real, developing new therapies for Alzheimer's is tough and funding is hard to come by. 💸💭 So, Jasti sold his profitable CDMO business for ₹6,313 crore to keep his drug discovery dreams alive. 💰💊 #NeverGiveUp #AlzheimersDrugStruggle #MoneyTalks #DrugDiscoveryGoals #HighFailureRate #ButWeStillTry #HustleHard #BigDreams #BigMoney #CDMOBusiness #Fortune #NeverStopTrying #AlzheimersAwareness #ClinicalTrials #Phase3 #Phase2Failure #SuvenLifeSciences #SUVN502 #SUVNG3031 #Samelisant #Narcolepsy #PandemicStruggles #FundingIssues #NeuroDegenerativeDiseases #Alzheimers #Dementia #Challenges #HumbleBrag #MoneyMoves #HumbleLangauge.
The CIN of Suven Life Sciences Limited is L24110TG1989PLC009713.
Suven Life Sciences Limited is headquartered at Door No. 8-2-334, 6Th Floor, Sde Serene Chambers Road No. 5, Avenue 7, Banjara Hills, Hyderabad, Telangana, 500034.
Suven Life Sciences Limited was incorporated on 09 March 1989.
The current directors of Suven Life Sciences Limited are
The primary industry of Suven Life Sciences Limited is Professional, Scientific And Technical.
Suven Life Sciences Limited is listed. It is listed on BSE: 530239 and NSE: SUVEN.
The authorized capital of Suven Life Sciences Limited is ₹50.00 Cr, and the paid-up capital is ₹22.75 Cr.
The compliance status of Suven Life Sciences Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX